Combination of thermally ablative focused ultrasound with gemcitabine controls breast cancer via adaptive immunity.

ABSTRACT:

Background

Triple-negative breast cancer (TNBC) remains recalcitrant to most targeted therapy approaches. However, recent clinical studies suggest that inducing tumor damage can render TNBC responsive to immunotherapy. We therefore tested a strategy for immune sensitization of murine TNBC (4T1 tumors) through combination of focused ultrasound (FUS) thermal ablation and a chemotherapy, gemcitabine (GEM), known to attenuate myeloid-derived suppressor cells (MDSCs).

Methods

We applied a sparse-scan thermally ablative FUS regimen at the tumor site in combination with systemically administered GEM. We used flow cytometry analysis to investigate the roles of monotherapy and combinatorial therapy in mediating local and systemic immunity. We also tested this combination in Rag1

SUBMITTER: Sheybani ND 

PROVIDER: S-EPMC7443308 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature